GLP-1-AMX™ is KweHealth’s innovative therapeutic platform designed to redefine the treatment of obesity and Type 2 diabetes. Building on the proven success of GLP-1–based therapies, GLP-1-AMX™ overcomes the critical barriers that have limited patient outcomes and long-term adherence.

At the foundation of GLP-1-AMX™ is enhanced stability and extended half-life, achieved through proprietary peptide engineering that protects against rapid degradation by DPP-4 and neutral endopeptidases. This innovation enables sustained glycemic control with less frequent dosing, empowering patients with a more convenient and durable treatment option.

GLP-1-AMX™ is also engineered for superior tissue distribution, allowing deeper penetration into key metabolic tissues. By broadening its reach beyond traditional GLP-1 targets, it delivers a more comprehensive impact on weight management and glucose regulation.

Crucially, GLP-1-AMX™ addresses one of the most significant hurdles of current GLP-1 therapies: tolerability. By minimizing gastrointestinal side effects, it enhances patient comfort and compliance, enabling more effective and sustained treatment at therapeutic doses.

The result is a transformative metabolic therapy that unites durability, distribution, efficacy, and tolerability into a single platform. GLP-1-AMX™ is positioned to lead a new era in cardiometabolic care, offering patients and providers a powerful tool to combat obesity, diabetes, and the spectrum of related disorders.

GLP-1-AMX™ — Extending durability, expanding reach, and elevating outcomes in metabolic health.